Suppr超能文献

使用扩散加权成像和灌注加权成像监测静脉注射重组组织型纤溶酶原激活剂治疗急性缺血性卒中的溶栓过程。

Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI.

作者信息

Schellinger P D, Jansen O, Fiebach J B, Heiland S, Steiner T, Schwab S, Pohlers O, Ryssel H, Sartor K, Hacke W

机构信息

Department of Neuroradiology, University of Heidelberg Medical School, Germany.

出版信息

Stroke. 2000 Jun;31(6):1318-28. doi: 10.1161/01.str.31.6.1318.

Abstract

BACKGROUND AND PURPOSE

Intravenous recombinant tissue plasminogen activator (rtPA) administration is an effective therapy for ischemic stroke when initiated within 3 hours and possibly up to 6 hours after symptom onset. To improve patient selection, a fast diagnostic tool that allows reliable diagnosis of hemorrhage and ischemia, vessel status, and tissue at risk at an early stage may be useful. We studied the feasibility of stroke MRI for the initial evaluation and follow-up monitoring of patients undergoing intravenous thrombolysis.

METHODS

Stroke MRI (diffusion- and perfusion-weighted imaging [DWI and PWI, respectively], magnetic resonance angiography, and T2-weighted imaging) was performed before, during, or after thrombolysis and on days 2 and 5. We assessed clinical scores (National Institutes of Health Stroke Scale [NIHSS], Scandinavian Stroke Scale [SSS], Barthel Index, and Rankin scale) at days 1, 2, 5, 30, and 90. Furthermore, we performed volumetric analysis of infarct volumes on days 1, 2, and 5 as shown in PWI, DWI, and T2-weighted imaging.

RESULTS

Twenty-four patients received rtPA within a mean time interval after symptom onset of 3.27 hours and stroke MRI of 3.43 hours. Vessel occlusion was present in 20 of 24 patients; 11 vessels recanalized (group 1), and 9 did not (group 2). The baseline PWI lesion volume was significantly larger (P=0.008) than outcome lesion size in group 1, whereas baseline DWI lesion volume was significantly smaller (P=0.008) than final infarct size in group 2. Intergroup outcome differed significantly for all scores at days 30 and 90 (all P<0.01). Intragroup differences were significant in group 1 for change in SSS and NIHSS between day 1 and day 30 (P=0.003) and for SSS only between day 1 and day 90 (P=0.004).

CONCLUSIONS

Stroke MRI provides comprehensive prognostically relevant information regarding the brain in hyperacute stroke. Stroke MRI may be used as a single imaging tool in acute stroke to identify and monitor candidates for thrombolysis. It is proposed that stroke MRI is safe, reliable, and cost effective; however, our data do not prove this assumption. Early recanalization achieved by thrombolysis can save tissue at risk if present and may result in significantly smaller infarcts and a significantly better outcome.

摘要

背景与目的

静脉注射重组组织型纤溶酶原激活剂(rtPA)在症状发作后3小时内甚至可能在6小时内开始使用时,是缺血性卒中的有效治疗方法。为了改善患者的选择,一种能够在早期可靠诊断出血、缺血、血管状况和危险组织的快速诊断工具可能会有所帮助。我们研究了卒中磁共振成像(MRI)用于接受静脉溶栓治疗患者的初始评估和随访监测的可行性。

方法

在溶栓前、溶栓期间或溶栓后以及第2天和第5天进行卒中MRI(分别为扩散加权成像和灌注加权成像[DWI和PWI]、磁共振血管造影和T2加权成像)。我们在第1、2、5、30和90天评估临床评分(美国国立卫生研究院卒中量表[NIHSS]、斯堪的纳维亚卒中量表[SSS]、巴氏指数和Rankin量表)。此外,我们对第1、2和5天的梗死体积进行了容积分析,如PWI、DWI和T2加权成像所示。

结果

24例患者在症状发作后平均3.27小时、卒中MRI检查后平均3.43小时接受了rtPA治疗。24例患者中有20例存在血管闭塞;11支血管再通(第1组),9支未再通(第2组)。第1组的基线PWI病变体积显著大于结局病变大小(P = 0.008),而第2组的基线DWI病变体积显著小于最终梗死灶大小(P = 0.008)。在第30天和第90天,所有评分的组间结局差异均有统计学意义(所有P < 0.01)。第1组中,第1天和第30天之间SSS和NIHSS的变化(P = 0.003)以及仅第1天和第90天之间的SSS变化(P = 0.004)存在组内差异。

结论

卒中MRI为超急性卒中的大脑提供了全面的与预后相关的信息。卒中MRI可作为急性卒中的单一成像工具,用于识别和监测溶栓候选者。有人提出卒中MRI是安全、可靠且具有成本效益的;然而,我们的数据并未证实这一假设。溶栓实现的早期再通如果存在可挽救危险组织,并可能导致梗死灶显著缩小和结局显著改善。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验